Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic retinopathy is the leading cause of blindness in the developed world. The causes of the disease are poorly understood. One of the earliest changes that occur in the retinas of diabetic patients, well before overt retinopathy is observed, is a reduction in light-evoked increases in blood flow in retinal vessels. The loss of this vascular response may lead to retinal hypoxia and it has been suggested that hypoxia could be a principal cause of diabetic retinopathy.

The long-term goals of this project are to determine whether decreased blood flow in diabetic patients and the resulting retinal hypoxia contributes to the development of diabetic retinopathy and whether restoration of normal blood flow in diabetic patients slows or prevents the development of retinopathy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Pimagedine

Criteria

Inclusion Criteria:

• Type 1 diabetes between 18 and 65 years of age

• Diabetes duration between 5 to 20 years.

• Normal report or minor findings on a dilated eye exam

• Healthy subjects on no medications

Exclusion Criteria:

Current diagnosis or history of:

• hypertension

• dyslipidemia

• epilepsy

• glaucoma or other ocular disease

• renal insufficiency/failure (creatinine >1.5 mg/dL)

• pregnancy or breastfeeding.

• smoker